Finerenone
Finerenone (pronounced as fi-ne-ren-one) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that is used in the treatment of chronic kidney disease (CKD) and heart failure (HF). It is developed by Bayer, a German multinational pharmaceutical company.
Etymology
The term 'Finerenone' is derived from its chemical structure and function. The prefix 'Finer-' is a modification of 'Fina-', which is a common prefix in the names of many pharmaceutical drugs. The suffix '-enone' refers to its chemical structure, which contains a double bond ('-ene') and a ketone group ('-one').
Pharmacology
Finerenone works by blocking the action of aldosterone, a hormone that can cause fluid retention and increase blood pressure. By blocking the action of aldosterone, Finerenone helps to reduce fluid retention and lower blood pressure, which can help to slow the progression of CKD and HF.
Related Terms
- Mineralocorticoid receptor antagonist (MRA): A type of drug that blocks the action of aldosterone.
- Aldosterone: A hormone that can cause fluid retention and increase blood pressure.
- Chronic kidney disease (CKD): A long-term condition where the kidneys do not work as well as normal.
- Heart failure (HF): A condition where the heart is unable to pump blood around the body effectively.
- Bayer: A German multinational pharmaceutical and life sciences company.
See Also
External links
- Medical encyclopedia article on Finerenone
- Wikipedia's article - Finerenone
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski